Oncotarget

Priority Research Papers:

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease

Rebecca Lamb, Bela Ozsvari, Camilla L. Lisanti, Herbert B. Tanowitz, Anthony Howell, Ubaldo E. Martinez-Outschoorn, Federica Sotgia, Michael P. Lisanti _

PDF |  HTML  |  Author Information

 

Metrics: PDF 15164 views  |   HTML 15950 views  |   ?  

here


Abstract

Rebecca Lamb1,2,*, Bela Ozsvari1,2,*, Camilla L. Lisanti3,**, Herbert B. Tanowitz4, Anthony Howell1,2, Ubaldo E. Martinez-Outschoorn5, Federica Sotgia1,2 and Michael P. Lisanti1,2

1 The Breakthrough Breast Cancer Research Unit, Institute of Cancer Sciences, University of Manchester, UK

2 The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, UK

3 The Moor Allerton Preparatory School, Didsbury, Manchester, UK

4 Departments of Pathology and Medicine, The Albert Einstein College of Medicine, Bronx, NY, USA

5 The Kimmel Cancer Center, Philadelphia, PA, USA

* These authors contributed equally to this study and should be considered as co-first authors

** provided the initial idea for this study

Correspondence:

Michael P. Lisanti, email:

Federica Sotgia, email:

Keywords: mitochondria, mitochondrial biogenesis, cancer stem cells, tumor initiating cells, antibiotics

Received: December 24, 2014 Accepted: January 15, 2015 Published: January 22, 2015

Abstract

Here, we propose a new strategy for the treatment of early cancerous lesions and advanced metastatic disease, via the selective targeting of cancer stem cells (CSCs), a.k.a., tumor-initiating cells (TICs). We searched for a global phenotypic characteristic that was highly conserved among cancer stem cells, across multiple tumor types, to provide a mutation-independent approach to cancer therapy. This would allow us to target cancer stem cells, effectively treating cancer as a single disease of “stemness”, independently of the tumor tissue type. Using this approach, we identified a conserved phenotypic weak point – a strict dependence on mitochondrial biogenesis for the clonal expansion and survival of cancer stem cells. Interestingly, several classes of FDA-approved antibiotics inhibit mitochondrial biogenesis as a known “side-effect”, which could be harnessed instead as a “therapeutic effect”. Based on this analysis, we now show that 4-to-5 different classes of FDA-approved drugs can be used to eradicate cancer stem cells, in 12 different cancer cell lines, across 8 different tumor types (breast, DCIS, ovarian, prostate, lung, pancreatic, melanoma, and glioblastoma (brain)). These five classes of mitochondrially-targeted antibiotics include: the erythromycins, the tetracyclines, the glycylcyclines, an anti-parasitic drug, and chloramphenicol. Functional data are presented for one antibiotic in each drug class: azithromycin, doxycycline, tigecycline, pyrvinium pamoate, as well as chloramphenicol, as proof-of-concept. Importantly, many of these drugs are non-toxic for normal cells, likely reducing the side effects of anti-cancer therapy. Thus, we now propose to treat cancer like an infectious disease, by repurposing FDA-approved antibiotics for anti-cancer therapy, across multiple tumor types. These drug classes should also be considered for prevention studies, specifically focused on the prevention of tumor recurrence and distant metastasis. Finally, recent clinical trials with doxycycline and azithromycin (intended to target cancer-associated infections, but not cancer cells) have already shown positive therapeutic effects in cancer patients, although their ability to eradicate cancer stem cells was not yet appreciated.

Author Information

Rebecca Lamb

Bela Ozsvari

Camilla L. Lisanti

Herbert B. Tanowitz

Anthony Howell

Ubaldo E. Martinez-Outschoorn

Federica Sotgia

Michael P. Lisanti
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3174


Copyright @ 2016 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC